title: Regulation of APP processing by intra- and intercellular signals.
abstract: APP processing appears to be under complex regulation. This regulation is apparently important under both normal and pathological conditions. Of direct clinical interest is the observation that A beta formation can be regulated by various means. This raises the possibility that altered APP processing may cause an increase in A beta formation in AD, and suggests that it may be possible to regulate the production of A beta as a therapeutic approach in AD. As an example of the utility of the latter approach, consider a patient carrying the Swedish APP mutation. If it is true that the cause of AD in such a patient is due to increased A beta production, then decreasing A beta production should delay the onset of the disease. Even in individuals where increased A beta formation is not the cause of AD but there is some other causes, such as the presence of an allele of apolipoprotein E which causes A beta accumulation and hence synaptic loss, decreasing A beta formation may be beneficial. It is of course a very long way from in vitro experiments to therapy. The current emphasis on studying APP processing in vivo represents the next step towards this goal.
authors.affiliation: Laboratory of Molecular and Cellular Neuroscience, Rockefeller University, New York, New York, USA 10021.
authors.forename: J D
authors.initials: JD
authors.lastname: Buxbaum
authors.forename: P
authors.initials: P
authors.lastname: Greengard
mesh_terms: D016564:Amyloid beta-Protein Precursor / Q000502:physiology*; D002118:Calcium / Q000502:physiology; D002468:Cell Physiological Phenomena; D006801:Humans; D007425:Intracellular Membranes / Q000502:physiology; D011499:Protein Processing, Post-Translational; D015398:Signal Transduction; D010738:Type C Phospholipases / Q000502:physiology
chemical_list: D016564:Amyloid beta-Protein Precursor; D010738:Type C Phospholipases; D002118:Calcium